ADVERTISEMENT
Real-World Use of PARP Inhibitor for First-line Maintenance in Newly Diagnosed Ovarian Cancer
Jinan Liu, MD, PhD, GlaxoSmithKline, Upper Providence, PA, described the use of first-line maintenance therapies among patients with ovarian cancer, and examined predictors of first-line of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor maintenance therapy use.
Transcript available on May 3rd.
Liu J, et al. Poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor first-line maintenance among patients with newly diagnosed advanced ovarian cancer in a real-world database. Presented at: the 2022 SGO Annual Meeting on Women’s Cancer; March 18-21, 2022. Poster 351. Dr Liu reports no disclosures.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Current Issue
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Subscribe
Advertisement
Advertisement
Advertisement
Recent Stories
Advertisement